ID   CD38_HUMAN              Reviewed;         300 AA.
AC   P28907; O00121; O00122; Q96HY4;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-NOV-2004, sequence version 2.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1;
DE            EC=3.2.2.6;
DE   AltName: Full=2'-phospho-ADP-ribosyl cyclase;
DE   AltName: Full=2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase;
DE            EC=2.4.99.20;
DE   AltName: Full=2'-phospho-cyclic-ADP-ribose transferase;
DE   AltName: Full=ADP-ribosyl cyclase 1;
DE            Short=ADPRC 1;
DE   AltName: Full=Cyclic ADP-ribose hydrolase 1;
DE            Short=cADPr hydrolase 1;
DE   AltName: Full=T10;
DE   AltName: CD_antigen=CD38;
GN   Name=CD38;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2319135;
RA   Jackson D.G., Bell J.I.;
RT   "Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell
RT   surface glycoprotein with an unusual discontinuous pattern of
RT   expression during lymphocyte differentiation.";
RL   J. Immunol. 144:2811-2815(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], NUCLEOTIDE SEQUENCE [MRNA]
RP   (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Esophageal carcinoma, and Pancreas;
RX   PubMed=9074508; DOI=10.1016/S0378-1119(96)00723-8;
RA   Nata K., Takamura T., Karasawa T., Kumagai T., Hashioka W., Tohgo A.,
RA   Yonekura H., Takasawa S., Nakamura S., Okamoto H.;
RT   "Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose
RT   hydrolase): organization, nucleotide sequence and alternative
RT   splicing.";
RL   Gene 186:285-292(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   SIMILARITY TO NADASE.
RX   PubMed=1471258; DOI=10.1016/0968-0004(92)90337-9;
RA   States D.J., Walseth T.F., Lee H.C.;
RT   "Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase
RT   and human lymphocyte antigen CD38.";
RL   Trends Biochem. Sci. 17:495-495(1992).
RN   [5]
RP   CHARACTERIZATION.
RX   PubMed=8253715;
RA   Takasawa S., Tohgo A., Noguchi N., Koguma T., Nata K., Sugimoto T.,
RA   Yonekura H., Okamoto H.;
RT   "Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte
RT   antigen CD38 and inhibition of the hydrolysis by ATP.";
RL   J. Biol. Chem. 268:26052-26054(1993).
RN   [6]
RP   ACTIVE SITE, AND MUTAGENESIS OF CYS-119; CYS-160; CYS-173 AND CYS-201.
RX   PubMed=7961800;
RA   Tohgo A., Takasawa S., Noguchi N., Koguma T., Nata K., Sugimoto T.,
RA   Furuya Y., Yonekura H., Okamoto H.;
RT   "Essential cysteine residues for cyclic ADP-ribose synthesis and
RT   hydrolysis by CD38.";
RL   J. Biol. Chem. 269:28555-28557(1994).
RN   [7]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [8]
RP   CATALYTIC ACTIVITY.
RX   PubMed=16690024; DOI=10.1016/j.bbrc.2006.04.096;
RA   Moreschi I., Bruzzone S., Melone L., De Flora A., Zocchi E.;
RT   "NAADP+ synthesis from cADPRP and nicotinic acid by ADP-ribosyl
RT   cyclases.";
RL   Biochem. Biophys. Res. Commun. 345:573-580(2006).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-100; ASN-209 AND ASN-219.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-219.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 45-300, AND DISULFIDE BONDS.
RX   PubMed=16154090; DOI=10.1016/j.str.2005.05.012;
RA   Liu Q., Kriksunov I.A., Graeff R., Munshi C., Lee H.C., Hao Q.;
RT   "Crystal structure of human CD38 extracellular domain.";
RL   Structure 13:1331-1339(2005).
RN   [14]
RP   VARIANT TRP-140.
RX   PubMed=9754820; DOI=10.1007/s001250051026;
RA   Yagui K., Shimada F., Mimura M., Hashimoto N., Suzuki Y., Tokuyama Y.,
RA   Nata K., Tohgo A., Ikehata F., Takasawa S., Okamoto H., Makino H.,
RA   Saito Y., Kanatsuka A.;
RT   "A missense mutation in the CD38 gene, a novel factor for insulin
RT   secretion: association with Type II diabetes mellitus in Japanese
RT   subjects and evidence of abnormal function when expressed in vitro.";
RL   Diabetologia 41:1024-1028(1998).
CC   -!- FUNCTION: Synthesizes the second messagers cyclic ADP-ribose and
CC       nicotinate-adenine dinucleotide phosphate, the former a second
CC       messenger for glucose-induced insulin secretion. Also has cADPr
CC       hydrolase activity. Also moonlights as a receptor in cells of the
CC       immune system.
CC   -!- CATALYTIC ACTIVITY: NAD(+) + H(2)O = ADP-D-ribose + nicotinamide.
CC       {ECO:0000269|PubMed:16690024}.
CC   -!- CATALYTIC ACTIVITY: NADP(+) + nicotinate = nicotinate-adenine
CC       dinucleotide phosphate + nicotinamide.
CC       {ECO:0000269|PubMed:16690024}.
CC   -!- ENZYME REGULATION: ATP inhibits the hydrolyzing activity.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type II membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P28907-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P28907-2; Sequence=VSP_000707, VSP_000708;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC   -!- TISSUE SPECIFICITY: Expressed at high levels in pancreas, liver,
CC       kidney, brain, testis, ovary, placenta, malignant lymphoma and
CC       neuroblastoma. {ECO:0000269|PubMed:9074508}.
CC   -!- DEVELOPMENTAL STAGE: Preferentially expressed at both early and
CC       late stages of the B and T-cell maturation. It is also detected on
CC       erythroid and myeloid progenitors in bone marrow, where the level
CC       of surface expression was shown to decrease during differentiation
CC       of blast-forming unit E to colony-forming unit E.
CC   -!- SIMILARITY: Belongs to the ADP-ribosyl cyclase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CD38 entry;
CC       URL="https://en.wikipedia.org/wiki/CD38";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CD38ID978ch4p15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M34461; AAA68482.1; -; mRNA.
DR   EMBL; D84276; BAA18964.1; -; mRNA.
DR   EMBL; D84277; BAA18965.1; -; mRNA.
DR   EMBL; D84284; BAA18966.1; -; Genomic_DNA.
DR   EMBL; BC007964; AAH07964.1; -; mRNA.
DR   CCDS; CCDS3417.1; -. [P28907-1]
DR   PIR; A43521; A43521.
DR   RefSeq; NP_001766.2; NM_001775.3. [P28907-1]
DR   UniGene; Hs.479214; -.
DR   PDB; 1YH3; X-ray; 1.91 A; A/B=45-300.
DR   PDB; 1ZVM; X-ray; 2.20 A; A/B/C/D=45-300.
DR   PDB; 2EF1; X-ray; 2.40 A; A/B=45-300.
DR   PDB; 2HCT; X-ray; 1.95 A; A/B=45-300.
DR   PDB; 2I65; X-ray; 1.90 A; A/B=45-300.
DR   PDB; 2I66; X-ray; 1.70 A; A/B=45-300.
DR   PDB; 2I67; X-ray; 1.71 A; A/B=45-300.
DR   PDB; 2O3Q; X-ray; 1.98 A; A/B=45-300.
DR   PDB; 2O3R; X-ray; 1.75 A; A/B=45-300.
DR   PDB; 2O3S; X-ray; 1.50 A; A/B=45-300.
DR   PDB; 2O3T; X-ray; 1.68 A; A/B=45-300.
DR   PDB; 2O3U; X-ray; 2.11 A; A/B=45-300.
DR   PDB; 2PGJ; X-ray; 1.71 A; A/B=45-300.
DR   PDB; 2PGL; X-ray; 1.76 A; A/B=45-300.
DR   PDB; 3DZF; X-ray; 2.01 A; A/B/C/D/E/F=45-300.
DR   PDB; 3DZG; X-ray; 1.65 A; A/B=45-300.
DR   PDB; 3DZH; X-ray; 1.60 A; A/B=45-300.
DR   PDB; 3DZI; X-ray; 1.73 A; A/B=45-300.
DR   PDB; 3DZJ; X-ray; 1.90 A; A/B=45-300.
DR   PDB; 3DZK; X-ray; 1.81 A; A/B=45-300.
DR   PDB; 3F6Y; X-ray; 1.45 A; A=45-300.
DR   PDB; 3I9M; X-ray; 1.75 A; A/B=45-300.
DR   PDB; 3I9N; X-ray; 2.01 A; A/B=45-300.
DR   PDB; 3OFS; X-ray; 2.20 A; A/B/C/D/E/F=46-300.
DR   PDB; 3RAJ; X-ray; 3.04 A; A=46-300.
DR   PDB; 3ROK; X-ray; 1.65 A; A/B=45-296.
DR   PDB; 3ROM; X-ray; 2.04 A; A/B=45-296.
DR   PDB; 3ROP; X-ray; 1.94 A; A/B=45-296.
DR   PDB; 3ROQ; X-ray; 2.10 A; A/B=45-296.
DR   PDB; 3U4H; X-ray; 1.88 A; A/B=45-300.
DR   PDB; 3U4I; X-ray; 2.12 A; A/B=45-300.
DR   PDB; 4CMH; X-ray; 1.53 A; A=45-300.
DR   PDB; 4F45; X-ray; 2.10 A; A/B=46-300.
DR   PDB; 4F46; X-ray; 1.69 A; A/B=46-300.
DR   PDB; 4OGW; X-ray; 2.05 A; A=46-300.
DR   PDB; 4TMF; X-ray; 2.05 A; A/B=50-300.
DR   PDB; 4XJS; X-ray; 2.80 A; A=46-300.
DR   PDB; 4XJT; X-ray; 2.60 A; A=46-300.
DR   PDB; 5F1K; X-ray; 2.30 A; A/B=45-300.
DR   PDB; 5F1O; X-ray; 2.20 A; A=46-300.
DR   PDB; 5F21; X-ray; 1.90 A; A=46-300.
DR   PDBsum; 1YH3; -.
DR   PDBsum; 1ZVM; -.
DR   PDBsum; 2EF1; -.
DR   PDBsum; 2HCT; -.
DR   PDBsum; 2I65; -.
DR   PDBsum; 2I66; -.
DR   PDBsum; 2I67; -.
DR   PDBsum; 2O3Q; -.
DR   PDBsum; 2O3R; -.
DR   PDBsum; 2O3S; -.
DR   PDBsum; 2O3T; -.
DR   PDBsum; 2O3U; -.
DR   PDBsum; 2PGJ; -.
DR   PDBsum; 2PGL; -.
DR   PDBsum; 3DZF; -.
DR   PDBsum; 3DZG; -.
DR   PDBsum; 3DZH; -.
DR   PDBsum; 3DZI; -.
DR   PDBsum; 3DZJ; -.
DR   PDBsum; 3DZK; -.
DR   PDBsum; 3F6Y; -.
DR   PDBsum; 3I9M; -.
DR   PDBsum; 3I9N; -.
DR   PDBsum; 3OFS; -.
DR   PDBsum; 3RAJ; -.
DR   PDBsum; 3ROK; -.
DR   PDBsum; 3ROM; -.
DR   PDBsum; 3ROP; -.
DR   PDBsum; 3ROQ; -.
DR   PDBsum; 3U4H; -.
DR   PDBsum; 3U4I; -.
DR   PDBsum; 4CMH; -.
DR   PDBsum; 4F45; -.
DR   PDBsum; 4F46; -.
DR   PDBsum; 4OGW; -.
DR   PDBsum; 4TMF; -.
DR   PDBsum; 4XJS; -.
DR   PDBsum; 4XJT; -.
DR   PDBsum; 5F1K; -.
DR   PDBsum; 5F1O; -.
DR   PDBsum; 5F21; -.
DR   ProteinModelPortal; P28907; -.
DR   SMR; P28907; -.
DR   BioGrid; 107390; 6.
DR   MINT; MINT-4536880; -.
DR   STRING; 9606.ENSP00000226279; -.
DR   BindingDB; P28907; -.
DR   ChEMBL; CHEMBL4660; -.
DR   DrugBank; DB09331; Daratumumab.
DR   GuidetoPHARMACOLOGY; 2766; -.
DR   iPTMnet; P28907; -.
DR   PhosphoSitePlus; P28907; -.
DR   SwissPalm; P28907; -.
DR   BioMuta; CD38; -.
DR   DMDM; 55977782; -.
DR   EPD; P28907; -.
DR   MaxQB; P28907; -.
DR   PaxDb; P28907; -.
DR   PeptideAtlas; P28907; -.
DR   PRIDE; P28907; -.
DR   DNASU; 952; -.
DR   Ensembl; ENST00000226279; ENSP00000226279; ENSG00000004468. [P28907-1]
DR   Ensembl; ENST00000502843; ENSP00000427277; ENSG00000004468. [P28907-2]
DR   GeneID; 952; -.
DR   KEGG; hsa:952; -.
DR   UCSC; uc003gol.2; human. [P28907-1]
DR   CTD; 952; -.
DR   DisGeNET; 952; -.
DR   GeneCards; CD38; -.
DR   HGNC; HGNC:1667; CD38.
DR   HPA; CAB002493; -.
DR   HPA; CAB025255; -.
DR   HPA; HPA022132; -.
DR   HPA; HPA052381; -.
DR   MIM; 107270; gene.
DR   neXtProt; NX_P28907; -.
DR   OpenTargets; ENSG00000004468; -.
DR   PharmGKB; PA26214; -.
DR   eggNOG; ENOG410IH8E; Eukaryota.
DR   eggNOG; ENOG4111W33; LUCA.
DR   GeneTree; ENSGT00390000017291; -.
DR   HOGENOM; HOG000293141; -.
DR   HOVERGEN; HBG005277; -.
DR   InParanoid; P28907; -.
DR   KO; K01242; -.
DR   OMA; CKNIYRP; -.
DR   OrthoDB; EOG091G0GI3; -.
DR   PhylomeDB; P28907; -.
DR   TreeFam; TF332530; -.
DR   BioCyc; MetaCyc:HS00103-MONOMER; -.
DR   BRENDA; 2.4.99.20; 2681.
DR   BRENDA; 3.2.2.5; 2681.
DR   Reactome; R-HSA-196807; Nicotinate metabolism.
DR   SABIO-RK; P28907; -.
DR   EvolutionaryTrace; P28907; -.
DR   GeneWiki; CD38; -.
DR   GenomeRNAi; 952; -.
DR   PRO; PR:P28907; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000004468; -.
DR   CleanEx; HS_CD38; -.
DR   ExpressionAtlas; P28907; baseline and differential.
DR   Genevisible; P28907; HS.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0050135; F:NAD(P)+ nucleosidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003953; F:NAD+ nucleosidase activity; TAS:Reactome.
DR   GO; GO:0061809; F:NAD+ nucleotidase, cyclic ADP-ribose generating; IEA:UniProtKB-EC.
DR   GO; GO:0016849; F:phosphorus-oxygen lyase activity; IEA:Ensembl.
DR   GO; GO:0016740; F:transferase activity; IEA:UniProtKB-KW.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0060292; P:long term synaptic depression; IEA:Ensembl.
DR   GO; GO:0019674; P:NAD metabolic process; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045779; P:negative regulation of bone resorption; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IMP:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IMP:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0033194; P:response to hydroperoxide; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0070555; P:response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0032570; P:response to progesterone; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; NAS:ProtInc.
DR   InterPro; IPR003193; ADP-ribosyl_cyclase.
DR   InterPro; IPR033567; CD38.
DR   PANTHER; PTHR10912; PTHR10912; 1.
DR   PANTHER; PTHR10912:SF9; PTHR10912:SF9; 1.
DR   Pfam; PF02267; Rib_hydrolayse; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Diabetes mellitus; Disulfide bond; Glycoprotein; Hydrolase; Membrane;
KW   NAD; NADP; Polymorphism; Receptor; Reference proteome; Signal-anchor;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    300       ADP-ribosyl cyclase/cyclic ADP-ribose
FT                                hydrolase 1.
FT                                /FTId=PRO_0000144066.
FT   TOPO_DOM      1     21       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     22     42       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     43    300       Extracellular. {ECO:0000255}.
FT   ACT_SITE    119    119       {ECO:0000269|PubMed:7961800}.
FT   ACT_SITE    201    201       {ECO:0000269|PubMed:7961800}.
FT   CARBOHYD    100    100       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    164    164       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    209    209       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    219    219       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   DISULFID     67     82       {ECO:0000269|PubMed:16154090}.
FT   DISULFID     99    180       {ECO:0000269|PubMed:16154090}.
FT   DISULFID    160    173       {ECO:0000269|PubMed:16154090}.
FT   DISULFID    254    275       {ECO:0000269|PubMed:16154090}.
FT   DISULFID    287    296       {ECO:0000269|PubMed:16154090}.
FT   VAR_SEQ     122    122       I -> K (in isoform 2).
FT                                {ECO:0000303|PubMed:9074508}.
FT                                /FTId=VSP_000707.
FT   VAR_SEQ     123    300       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:9074508}.
FT                                /FTId=VSP_000708.
FT   VARIANT     140    140       R -> W (seems to contribute to the
FT                                development of type II diabetes; 50%
FT                                reduction in activity; dbSNP:rs1800561).
FT                                {ECO:0000269|PubMed:9754820}.
FT                                /FTId=VAR_001323.
FT   MUTAGEN     119    119       C->K: Loss of cADPr hydrolase activity.
FT                                {ECO:0000269|PubMed:7961800}.
FT   MUTAGEN     119    119       C->R,E,A: Loss of cADPr hydrolase and
FT                                ADP-ribosyl cyclase activity.
FT                                {ECO:0000269|PubMed:7961800}.
FT   MUTAGEN     160    160       C->A: Loss of cADPr hydrolase and ADP-
FT                                ribosyl cyclase activity.
FT                                {ECO:0000269|PubMed:7961800}.
FT   MUTAGEN     173    173       C->A: Loss of cADPr hydrolase and ADP-
FT                                ribosyl cyclase activity.
FT                                {ECO:0000269|PubMed:7961800}.
FT   MUTAGEN     201    201       C->D,K,A: Loss of cADPr hydrolase and
FT                                ADP-ribosyl cyclase activity.
FT                                {ECO:0000269|PubMed:7961800}.
FT   MUTAGEN     201    201       C->E: Loss of cADPr hydrolase activity.
FT                                {ECO:0000269|PubMed:7961800}.
FT   CONFLICT     49     49       Q -> T (in Ref. 1; AAA68482).
FT                                {ECO:0000305}.
FT   STRAND       51     53       {ECO:0000244|PDB:3F6Y}.
FT   HELIX        59     73       {ECO:0000244|PDB:3F6Y}.
FT   HELIX        75     77       {ECO:0000244|PDB:2O3S}.
FT   HELIX        82     93       {ECO:0000244|PDB:3F6Y}.
FT   STRAND       94     96       {ECO:0000244|PDB:3RAJ}.
FT   HELIX        98    100       {ECO:0000244|PDB:3F6Y}.
FT   HELIX       103    106       {ECO:0000244|PDB:3F6Y}.
FT   HELIX       107    112       {ECO:0000244|PDB:3F6Y}.
FT   HELIX       119    121       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      122    127       {ECO:0000244|PDB:2O3S}.
FT   STRAND      132    134       {ECO:0000244|PDB:3F6Y}.
FT   HELIX       136    141       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      142    144       {ECO:0000244|PDB:3RAJ}.
FT   HELIX       145    147       {ECO:0000244|PDB:3F6Y}.
FT   HELIX       149    154       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      165    167       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      171    173       {ECO:0000244|PDB:3F6Y}.
FT   TURN        176    179       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      181    183       {ECO:0000244|PDB:3F6Y}.
FT   HELIX       184    199       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      202    209       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      212    216       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      218    220       {ECO:0000244|PDB:2EF1}.
FT   HELIX       221    224       {ECO:0000244|PDB:3F6Y}.
FT   HELIX       227    229       {ECO:0000244|PDB:3F6Y}.
FT   TURN        232    234       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      235    243       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      246    249       {ECO:0000244|PDB:3F6Y}.
FT   HELIX       253    255       {ECO:0000244|PDB:3F6Y}.
FT   HELIX       257    268       {ECO:0000244|PDB:3F6Y}.
FT   STRAND      272    278       {ECO:0000244|PDB:3F6Y}.
FT   HELIX       281    289       {ECO:0000244|PDB:2O3S}.
FT   TURN        291    293       {ECO:0000244|PDB:3DZG}.
FT   HELIX       294    296       {ECO:0000244|PDB:5F21}.
SQ   SEQUENCE   300 AA;  34328 MW;  47BBE38C3DE3E6AA CRC64;
     MANCEFSPVS GDKPCCRLSR RAQLCLGVSI LVLILVVVLA VVVPRWRQQW SGPGTTKRFP
     ETVLARCVKY TEIHPEMRHV DCQSVWDAFK GAFISKHPCN ITEEDYQPLM KLGTQTVPCN
     KILLWSRIKD LAHQFTQVQR DMFTLEDTLL GYLADDLTWC GEFNTSKINY QSCPDWRKDC
     SNNPVSVFWK TVSRRFAEAA CDVVHVMLNG SRSKIFDKNS TFGSVEVHNL QPEKVQTLEA
     WVIHGGREDS RDLCQDPTIK ELESIISKRN IQFSCKNIYR PDKFLQCVKN PEDSSCTSEI
//
